# British Pharmacopoeia 2000

Volume 3

# British Pharmacopoeia (Veterinary) 2000

Published on the recommendation of the Medicines Commission pursuant to the Medicines Act 1968 and notified in draft to the European Commission in accordance with Directive 98/34/EEC

The monographs of the Third Edition of the European Pharmacopoeia (1997), as amended by the Supplement 2000 published by the Council of Europe in September 1999, are reproduced either in this edition of the British Pharmacopoeia (Veterinary) or in the associated edition of the British Pharmacopoeia see General Notices, page 3

Effective date: 1 December 2000 see Notices, page vi

London: The Stationery Office

In respect of Great Britain:

THE DEPARTMENT OF HEALTH

THE MINISTRY OF AGRICULTURE, FISHERIES AND FOOD

In respect of Northern Ireland:

THE DEPARTMENT OF HEALTH, SOCIAL SERVICES AND PUBLIC SAFETY

THE DEPARTMENT OF AGRICULTURE AND RURAL DEVELOPMENT

© Crown Copyright 2000

Published by The Stationery Office under licence from the Controller of Her Majesty's Stationery Office for the Department of Health on behalf of the Agriculture Ministers

Applications for reproduction should be made in writing to The Copyright Unit, Her Majesty's Stationery Office, St Clements House, 2 - 16 Colegate, Norwich NR3 1BQ.

First Published 2000

British Pharmacopoeia Commission

Office:

Market Towers 1 Nine Elms Lane London SW8 5NQ

Telephone: +44 (0)20 7273 0561 +44 (0)20 7273 0566

Fax:

bpcom@mca.gov.uk

E-mail:

Web site:

Laboratory:

Government Buildings Block 2, Honeypot Lane Stanmore Middlesex HA7 1AY

Fax:

Telephone: +44 (0)20 7972 3609

E-mail:

+44 (0)20 8951 3069 queries@bpclab.co.uk

Web site: www.bpclab.co.uk

Dd.....

ISBN 0 11 322320 X

Printed in the United Kingdom by the Stationery Office Limited under the authority and superintendence of the Controller of Her Majesty's Stationery Office and Queen's Printer of Acts of Parliament

## British Pharmacopoeia (Veterinary) 2000

#### **Notices**

Any reference to a monograph, an appendix or a reagent that is not contained within this edition of the British Pharmacopoeia (Veterinary) is to be construed as a reference to the said monograph, appendix or reagent contained within the British Pharmacopoeia.

Contents

The term 'British Pharmacopoeia', used without qualification, means the British Pharmacopoeia 2000 modified as necessary by amendments.

Where a preparation that is the subject of a monograph in the British Pharmacopoeia is supplied for use in veterinary practice, the standards of the British Pharmacopoeia apply, unless otherwise justified and authorised.

The designation 'British Pharmacopoeia (Veterinary)' [BP(Vet)] may be used in place of the designation 'British Pharmacopoeia' [BP] for a preparation complying with a monograph in the British Pharmacopoeia, where such a preparation is supplied for use in veterinary practice with the approval of the competent authority.

Monographs of the European Pharmacopoeia are distinguished by a chaplet of stars against the title. The term European Pharmacopoeia, used without qualification, means the third edition of the European Pharmacopoeia comprising, unless otherwise stated, the main volume, published in 1996 as amended by any subsequent supplements and revisions.

#### Patents

In this Pharmacopoeia certain drugs and preparations have been included notwithstanding the existence of actual or potential patent rights. In so far as such substances are protected by Letters Patent their inclusion in this Pharmacopoeia neither conveys, nor implies, licence to manufacture.

#### Effective dates

Much of the material in this edition enters into force on 1 December 2000 but certain material that has been published earlier by Gazette Notices became effective on the date stated in the relevant entry.

# Mendershing Hen Reitish Pharmaconomia Comprission

DSRT med Commission Britishi Pharmacopoidia Commission is appointed by the Secretary

# lasigoloi of State Concerned, with health in Great Britain, the Minister of shyladrants to vices vin La griculture of Fisheries and Forest Concerned to the lath, Social

The British Pharmacopoeia (Veterinary) 2000 is published for the Agriculture Ministers on the recommendation of the Medicines Commission in accordance with section 99(6) of the Medicines Act 1968.

The Medicines Commission wishes to record its appreciation for the services of all who have contributed to the preparation of this work.

Together with the British Pharmacopoeia 2000, to which it is a companion volume, it should be of great value to all those concerned with the quality of materials used in the practice of veterinary medicine.

Zarradan 104, names and the preparation under that section as given effect by slatigeoff description 102(3), of the Act of any amendments of any published list

(d) the proparation under section 99(8)(b) of the Act of any others of the Act of the Ac

Ramadon Remarks) The preparation and enseation (29(3)(b) of the Act, as given effect investign, the control of the Act, as given effect investign, the control of any amendments to any such

qqom Smrad To San Members of the British Pharmacopoeia Commission are appointed by mining the property of the Medicines of the Medicines of the Medicines Commission Appointments are usually for a frequency term of 4.

A Director of Quality Assurance in the Pharmaceutical Industry

G D Rees! BPharm PhD MRPharmS CChem MRSC FIQA

A D Woolfson' BSc PhD CChem FRSC MPSNI Professor of Pharmaceiltics, Queens University of Belfast

Scientific Director: R.C. Hutton BSe PhD CChem FRSC

Term of office ends 31 December 2001

### British Pharmacopoeia Commission

The British Pharmacopoeia Commission is appointed by the Secretary of State concerned with health in Great Britain, the Minister of Agriculture, Fisheries and Food, the Department of Health, Social Services and Public Safety for Northern Ireland and the Department of Agriculture and Rural Development for Northern Ireland, acting jointly, in exercise of their powers under section 4 of the Medicines Act 1968.

The duties of the British Pharmacopoeia Commission are as follows:

- (a) the preparation under section 99(1) of the Act of any new edition of the British Pharmacopoeia;
- (b) the preparation under section 99(1) of the Act, as given effect by section 102(1) thereof, of any amendments of the edition of the British Pharmacopoeia published in 1968 or any new edition of it;
- the preparation under section 100 of the Act (which provides for the preparation and publication of lists of names to be used as headings to monographs in the British Pharmacopoeia) of any list of names and the preparation under that section as given effect by section 102(3) of the Act of any amendments of any published list;
  - (d) the preparation under section 99(3)(b) of the Act of any compendium or any new edition thereof;
  - (e) the preparation under section 99(3)(b) of the Act, as given effect by section 102(1) thereof, of any amendments to any such compendium.

Members of the British Pharmacopoeia Commission are appointed by Ministers, having regard to recommendations made by the Medicines Commission. Appointments are usually for a (renewable) term of 4 years.

# Membership of the British Pharmacopoeia Commission

Chairman: D H Calam<sup>1</sup> OBE MA DPhil HonMRPharmS CChem FRSC
European Co-ordinator, National Institute for Biological
Standards and Control; Visiting Professor, University of Strathclyde

Vice-Chairman: J A Goldsmith<sup>1</sup> BSc PhD CChem FRSC FIQA
Formerly a Director of Technical Operations in the Pharmaceutical
Industry; Visiting Professor, University of Strathclyde

A H Andrews<sup>1</sup> BVetMed PhD MRCVS Veterinary Consultant

S Barton<sup>2</sup> BA DPhil BM BCh DCH DRCOG MRCGP MRCP General practitioner; formerly Medical Director at the National Prescribing Centre

D I R Begg¹ FRPharmS FIQA MCPP

Consultant in Pharmaceutical Quality Assurance; Visiting Professor,
University of Strathclyde

A F Fell<sup>1</sup> BPharm PhD FRPharmS CChem FRSC FIQA

Professor of Pharmaceutical Chemistry, University of Bradford

V Fenton-May<sup>1</sup> BPharm MI PharmM FRPharmS Specialist Quality Controller to the Welsh Hospitals

A M T Lee<sup>1</sup> BVMS PhD MRCVS

A member of the Veterinary Medicines Directorate

J M Midgley<sup>1</sup> OBE BSc MSc PhD FRPharmS CChem FRSC

Professor of Pharmaceutical and Medicinal Chemistry, University of

Strathclyde

A C Moffat<sup>1</sup> BPharm PhD DSc CChem FRSC FRPharmS MCPP Chief Scientist, Royal Pharmaceutical Society of Great Britain

N Randall<sup>1</sup> PhD CChem FRSC FIQA

A Director of Quality Assurance in the Pharmaceutical Industry

G D Rees<sup>1</sup> BPharm PhD MRPharmS CChem MRSC FIQA A Director of Quality Assurance in the Pharmaceutical Industry

A D Woolfson<sup>1</sup> BSc PhD CChem FRSC MPSNI Professor of Pharmaceutics, Queens University of Belfast

Secretary and Scientific Director: R

Scientific Director: R C Hutton BSc PhD CChem FRSC

<sup>&</sup>lt;sup>1</sup>Term of office ends 31 December 2001

<sup>&</sup>lt;sup>2</sup> Resigned March 1999

# Membership of Committees and Consultative Groups

The Commission appointed the following Committees and Corresponding Consultative Groups to advise it in carrying out its duties. Membership has changed from time to time; the lists below include all who have served during the period 1999 to 2000.

#### COMMITTEES

A: Medicinal Chemicals: N Randall (Chairman), G D Rees (Vice-Chairman), L Anderson, A L Barber, T G Beaumont, J C Berridge, A C Caws, A G Davidson, W J Lough, A J Woolfe

B: Medicinal Chemicals: A F Fell (Chairman), J M Midgley (Vice-Chairman), F Breslin, H B Davis, T Duffy,

B M Everett, A Holbrook, A Hutt, M A Lee, B Midcalf, S A Norton, M Turgoose

C: General Chemicals: J M Midgley (Chairman), J A Goldsmith (Vice-Chairman), S K Branch,

A C Cartwright, B M Everett, C T Goddard, P Henrys, D J Malpas, C Mroz,

I D Newton, A R Rixon, J Seaton, J M Sprake, M J Tait

D: Medicinal Chemicals: J A Goldsmith (Chairman), J F Chissell (Vice-Chairman), G P R Carr, A Holbrook,

W J Mossop, R A Packer, G F Phillips, W J Poling, W K L Pugh, G Skellern,

A A Wagland, I R Williams

E: Antibiotics: G D Rees (Chairman), D H Calam (Vice-Chairman), D Adams, J F Chissell,

J Dolman, A M French, K J Leiper, W Mann, W McLean, C G Taylor, I R Williams

(Corresponding member R K Howard)

G: Crude Drugs and Galenicals: A C Moffat (Chairman), L A Anderson (Vice-Chairman), G Blunden,

A G Davidson, K Helliwell, P J Houghton, B P Jackson, P Linley, W McLean,

AO I D Phillipson, A R Rixon, E Williamson

H: Biological Materials: DH Calam (Chairman), N Randall (Vice-Chairman), KJ Ayling, TW Barrowcliffe,

A F Bristow, B Cuthbertson, T Forsey, B P Hughes, D Hughes, P Sheppard,

T J Snape, W J Tarbit, L Tsang

(Corresponding members K R Butterworth, S Poole, L W Whitehouse)

J: Immunological Products: A M T Lee (Chairman), M J Corbel, M A Dow, I G S Furminger, M L Kavanagh,

A M Pickett, A H Thomas, P W Wells, D Wood

(Corresponding member E Griffiths)

M: Microbiology: R J Pinney (Chairman), V Fenton-May (Vice-Chairman), B Alexander, R Baird,

A L Davison, D P Hargreaves, W L Hooper, R Johnson, M G Lee, B R Matthews,

W McLean, M P Summers

N: Nomenclature: M A Simmonds (Chairman), D H Calam (Vice-Chairman), J K Aronson, S Barton,

D Cousins, E W Godly, P W Golightly, H McNulty, D K Mehta, G P Moss,

Minima specific of GF Phillips, R Thorpe, A Wade

(Corresponding members E M Cortés Montejano, S Kopp-Kubel)

P: Pharmacy DIR Begg (Chairman), A D Woolfson (Vice-Chairman), M C Allwood,

G Davison, K Dobson, G Eccleston, R L Horder, M C R Johnson, M G Lee,

B R Matthews, G Smith, M P Summers, R Withington, P Wood

(Corresponding member I J McGilveray)

Charles arrange formand many to manager y

Term of office ends 31 December 2001

#### ALACA WIAGAS CAULA

#### CONSULTATIVE GROUPS

L: Surgical Materials: J M Midgley (Chairman), J Chaston, G J Collyer, D J Harris, D Metcalfe,

P Newlands, M Parkin, K Rawlings, S Thomas

R: Radioactive Materials: A F Fell (Chairman), S R Hesslewood, D Lui, A M Millar, R D Pickett,

A E Theobald, S Waters

Members of staff of the Commission who have taken part in the

production of this edition include:

Secretariat: M L Rabouhans, R B Trigg, H J Judd, M Vallender, P Holland,

F J Swanson, R Middleton, H Martin, E A Meff

Laboratory: A Islam, D C Brougham, R L Turner, C J Woollam, P K Dhanial,

T Morarji, C M Shah, R Mannan, V Pathak, M Barrett, A Ferrão, W Jeffries

Administrative: B F Delahunty, T Garrett, J Peters, S Canciglia, A Chapman

nat any reference to a monograph, appendix or reagent not co ithin this volume is to be construed as a reference to the said

Pharmacopoeia 2000.

This new edition together with the British Pharmacopoeia 20 contains all the monographs of the 3<sup>rd</sup> edition of the European

Pharmacopocia as amended by the Supplement 2000. Users of the

therefore benefit by finding within these two comprehensively indexe

editions all current pharmacopoeial standards for veterinary medicin used within the United Kingdom.

The effective date for this edition, which supersedes the British

Pharmacopoela (Veterinary) 1999 as amended by Amendments a

No. 1, is 1st December 2000 unless otherwise stated for an entry by an italicised statement showing the month and year of its implementation

reproduced from the European Pharmacopoeia and are located belo

the chaplet of stars that appears alongside the monograph title, for

Where a monograph which appeared previously in an earlier edition of the British Pharmacopoeia (Veterinary) has not been included in this new addition it remains effective in accordance with section 65(4)

of the Medicines Act 1968.

A list of monographs included within this pharmacopoeia for the first time is given at the end of this introduction. It includes 3 new monographs reproduced from the 1999 supplement of the European

# Introduction Introduction

edt yd bewollof era vedt. nelienteader this list indicates the sections of sections. of each mono-

eacht vinc of nadt radter begileb sort of the Samueles of the European Pharmacopoeia as This edition of the British Pharmacopoeia (Veterinary) has been prepared by the British Pharmacopoeia Commission in accordance with the Medicines (British Pharmacopoeia Commission) Amendment Order 1982 (SI 1982 No. 1335). This empowers the British Pharmabeabilist as middly siegge copoeia Commission to prepare a compendium under section 99(3)(b) at the Medicines Act 1968 containing information relating to substances and articles which are or may be used in the practice of modified visiting risks and the veterinary medicine or veterinary surgery. Under the terms of section landilibbs standard 65 of the Medicines Act 1968 it is an offence to sell or supply a In the Jall a ya) habba assemedicinal product in the United Kingdom that is the subject of a To move and middle days monograph in the Pharmacopoeia if that product does not comply with sisogosamana assort the standards specified in the monograph.

This edition is published as a companion volume to the British Pharmacopoeia 2000 and thus contains only those monographs for substances and preparations used exclusively or predominantly in veterinary medicine within the United Kingdom, together with such oals at tall should A with additional texts as are necessary to support them. It therefore follows s approved sid I amounted that any reference to a monograph, appendix or reagent not contained giand drive axest bodies within this volume is to be construed as a reference to the said (vasmissis)) sisono monograph, appendix or reagent contained within the British Pharmacopoeia 2000.

> This new edition together with the British Pharmacopoeia 2000 contains all the monographs of the 3<sup>rd</sup> edition of the European Pharmacopoeia as amended by the Supplement 2000. Users of the British Pharmacopoeia and British Pharmacopoeia (Veterinary) therefore benefit by finding within these two comprehensively indexed editions all current pharmacopoeial standards for veterinary medicines used within the United Kingdom.

#### Effective date

The effective date for this edition, which supersedes the British Pharmacopoeia (Veterinary) 1999 as amended by Amendments sheet No. 1, is 1st December 2000 unless otherwise stated for an entry by an italicised statement showing the month and year of its implementation. Such italicised statements are given for certain monographs reproduced from the European Pharmacopoeia and are located below and all dasagonoms to the chaplet of stars that appears alongside the monograph title, for British Pharmacopoeia is sc. '00/1' alqmaxa, veterinary medicine the

Where a monograph which appeared previously in an earlier edition and animismed sold of the British Pharmacopoeia (Veterinary) has not been included in bear ed of (1947) 981 (ver this new edition it remains effective in accordance with section 65(4) a stady [98] sison of the Medicines Act 1968.

#### **Additions and Revisions**

A list of monographs included within this pharmacopoeia for the first time is given at the end of this introduction. It includes 3 new monographs reproduced from the 1999 supplement of the European Pharmacopoeia.

Monographs which have been amended technically by means of this edition are also listed at the end of this introduction. For the benefit of the reader this list indicates the section, or sections, of each monograph which has/have been revised.

#### European Pharmacopoeia

All monographs of the 3<sup>rd</sup> edition of the European Pharmacopoeia as amended by Supplement 2000 which are used in veterinary practice but not normally in human medicine in the United Kingdom, are reproduced in this edition. Each of these monographs is signified by an European chaplet of stars alongside its title. Additionally, explicit reference is made to the European Pharmacopoeia within an italicised introductory statement. The entire European Pharmacopoeia text is then bounded by two horizontal lines bearing the symbol 'Ph Eur'.

The European texts have been reproduced in their entirety without a vigure to the editorial modification but, where deemed appropriate, additional statements of relevance to UK usage have been added (eg a list of BP discount of the event of doubt of interpretation in any text of the European Pharmacopoeia, the text published in English under the direction of the Council of Europe should be consulted.

Correspondence between the general methods of the European Pharmacopoeia and the appendices of the British Pharmacopoeia awollo provided at the beginning of the appendices section. This provides a full listing of the European Pharmacopoeia method texts with their British Pharmacopoeia and British Pharmacopoeia (Veterinary) equivalents.

# Pharmacopoeial Requirements

Pharmacopoeial requirements for articles used in veterinary medicine are established on the same basis as those used in human medicine. A proper understanding of the basis upon which these requirements are established is essential for their application and advice is provided within the General Notices of the British Pharmacopoeia (Veterinary) and the Supplementary Chapters to the British Pharmacopoeia. It should be noted that no requirement of the Pharmacopoeia can be taken in isolation. A valid interpretation of any particular requirement depends upon it being read in the context of (i) the monograph as a whole, (ii) the specified method of analysis, (iii) adapted on the relevant General Notices and (iv) where appropriate, the relevant would be associated in the context of the relevant general monograph.

Where a preparation which is the subject of a monograph in the British Pharmacopoeia is supplied for use in veterinary medicine the standards of the British Pharmacopoeia apply unless otherwise justified and authorised. Attention is drawn to the Notice permitting the designation British Pharmacopoeia (Veterinary) [BP (Vet)] to be used in place of the designation British Pharmacopoeia [BP] where a preparation complying with the British Pharmacopoeia is supplied for use in veterinary medicine with the approval of the competent authority.

General Monographs The General Monographs, which are applicable only to veterinary ton soob sail ain T 0001 (16 dosage forms, are grouped together within this volume at the beginnA spage and a ning of the Formulated Preparations section. They are followed by the dos recommended in alphabetical order. The General Monographs of the European Pharmacopoeia apply to all individual dosage forms of the type defined rather than to only those preparations for which a specific monograph is described (see the General Notices).

Acknowledgements The British Pharmacopoeia Commission is greatly indebted to the members of its advisory Committees and Consultative Groups without whose dedicated enthusiasm and assistance this edition could not have been prepared. Close co-operation has continued with many organisations at home and overseas. These include the Veterinary Medicines Directorate, the Medicines Control Agency (of which the Pharmacopoeia secretariat and laboratory staff are a part), the National Institute for Biological Standards and Control, the Royal Pharmaceutical Society of Great Britain, the National Office of Animal Health, the Association of the British Pharmaceutical Industry, the European Pharmacopoeia Commission, the Therapeutic Goods Administration (Australia), the Health Protection Branch of the Canadian Department of Health and Welfare, the Committee of Revision of the United States Pharmacopeia, the Essential Drugs and Other Medicines Department of the World Health Organization (WHO) and the WHO Collaborating Centre for Chemical Reference Substances.

#### Additions

The following monographs of the British Pharmacopoeia (Veterinary) 2000 were not included in the British Pharmacopoeia (Veterinary) 1999.

Medicinal and Pharmaceutical Substances Detomidine Hydrochloride\* Xylazine Hydrochloride\*

Immunological Products Avian Paramyxovirus 3 Vaccine, Inactivated\*

#### Omissions

The following monographs of the British Pharmacopoeia (Veterinary) 1999 are not included in the British Pharmacopoeia (Veterinary) 2000.

Formulated Preparations Amprolium and Ethopabate Premix Furazolidone Oral Suspension Furazolidone Premix Tiabendazole Oral Suspension Triamcinolone Acetonide Injection

#### Immunological Products

African Horsesickness Vaccine, Living Bluetongue Vaccine, Living Brucella Abortus (Strain 19) Vaccine, Living Brucella Abortus (Strain 45/20) Vaccine, Inactivated Canine Contagious Hepatitis Vaccine, Inactivated Contagious Bovine Pleuropneumonia Vaccine, Living Rinderpest Vaccine, Living Salmonella Choleraesuis Vaccine, Living Johnin Purified Protein Derivative

Technical Changes The following monographs in the BP(Vet) 2000 have been technically -rised and its actually and amended since the publication of the BP(Vet) 1999. This list does not and vel bewolfol and yell minclude revised monographs of the European Pharmacopoeia. An rebio leaded dis ai be indication of the nature of the change or the section of the monograph His or vices a socio as a that has been changed is given in italic type in the right hand column.

#### Medicinal and Pharmaceutical Substances

Fluanisone (Characteristics, Identification) Oxfendazole (Replaced by Ph Eur monograph) Silica in Dimeticone Suspension (Replaced by BP monograph for Simeticone for Oral Use)

#### Formulated Preparations: Specific Monographs

Levamisole Injection (Acidity) vanam dilw bound Procaine Benzylpenicillin Intramammary

and overe enoising include the Veterinary (Identification)

#### and doldwife) years Agency (of which the

Contagious Pustular Dermatitis Vaccine,

Living (Revision of most sections) Louping-ill Vaccine (Revision of most sections)

Lungworm (Dictyocaulus Viviparus)

ed vusubal festuseem Oral Vaccine, Living (Revision of most sections)

Ovine Enzootic Abortion Vaccine,

Inactivated (Revision of most sections)

## Contents

Any reference to a monograph, an appendix or a reagent that is not	PAGE
contained within this edition of the British Pharmacopoeia (Veterinary is to be construed as a reference <b>SADITOM</b> monograph, appendix or	vi
reagent contained within the Bri SCHARA copoeia.	vii
BRITISH PHARMACOPOEIA COMMISSION	ned for the viii
INTRODUCTION	edicines
M and to (where a preparation that is the subject of a monograph in the British  Pharmacopoela is suBOITON LARAMAD any practice, the standards	edicines Act <sup>xIII</sup>
bas bailish British Pharmacon RHARADONOM therwise justified and	eciation for 29
Medicinal and Pharmaceutical Substances	
Formulated Preparations: General Monographs	en it is a seconderned
19000000000000000000000000000000000000	
where such a preparation and a properties with the approval of user language with the user la	
Monographs of the European Materials are distinguished by a	
sieogosamiada naegos INFRARED REFERENCE SPECTRA	S1
used without qualification, "SASIGNATION of the European	A1
Pharmacopoeia comprising, unless otherwise stated, the main volume, published in 1996 as amended by arX3Q/XIquent supplements and	A25

In this Pharmacopoeia certain drugs and preparations have been included notwithstanding the existence of actual or potential patent rights. In so far as such substances are protected by Letters Patent their inclusion in this Pharmacopoeia neither conveys, nor implies, licence to manufacture.

Effective dates

Much of the material in this edition enters into force on 1 December 2000 but certain material that has been published earlier by Gazette Motices became effective on the date stated in the relevant entry.

# **General Notices**

The Buildin Pharmacopoeia (Veterinary) completes The entire text within this sdestrone Meterence should be made to the out of Europe text debution is included for the even deficiency in the base of the type of type of the type of type of the type of ty 1.6 Units of the International System (SI)

#### Contents of the General Notices

Part I

Italic introduction

European Pharmacopoeia

Part II

Italic introduction

Official Standards

Expression of Standards

Temperature

Weights and Measures

Atomic Weights

Constant Weight

Expression of Concentrations

Water Bath

Reagents

Indicators

Caution Statements

Titles

Chemical Formulae

Definition

Production

Manufacture of Formulated Preparations

Freshly and Recently Prepared

Methods of Sterilisation

Water

Excipients

Colouring Agents

Antimicrobial Preservatives

Characteristics

Solubility

Identification

Assays and Tests

Biological Assays and Tests

Storage

Labelling

Action and Use

Antibiotics Intended for use in the

Manufacture of Intramammary Infusions

Crude Drugs

Part III

Italic introduction

General Notices of the European

Pharmacopoeia

1.1 General Statements

Conventional terms

1.2 Other Provisions Applying to General

Chapters and Monographs

Quantities

Apparatus and procedures

Water-bath

Drying and ignition to constant mass

Reagents

Solvents

Expression of content

Temperature

1.3 General Chapters

Containers

1.4 Monographs

Titles

Relative atomic and molecular masses

Definition

Limits of content

Vegetable drugs

Production

Characters

Solubility

Identification

Tests and assays

Scope

Calculation

Limits

Indication of permitted limits of

impurities

Vegetable drugs

Equivalents

Storage

Labelling

Warnings

Impurities

Critical physical properties

Reference substances, reference

preparations and reference

spectra

Chemical reference substances

Biological reference preparations

Reference spectra

1.5 Abbreviations and Symbols

1.6 Units of the International System (SI)

Used in the Pharmacopoeia and

Equivalence With Other Units